Rope exercise.

Biologics in Rotator Cuff, Meniscus, Cartilage and Osteoarthritis Article

by Uncategorized
Rope exercise.

Drs. Anz, Hackel, Nilssen, and Andrews authored an article regarding the application of biologics in sports medicine which was published this month in the Journal of the American Academy of Orthopaedic Surgery.  

The article entitled “Application of biologics in the treatment of the rotator cuff, meniscus, cartilage, and osteoarthritis” reviewed the current status of the use of platelet-rich plasma, bone marrow aspirate, and stem cells within sports medicine.

What can stem cells do?

There is evidence that these technologies are going to influence the way that orthopaedic surgeons practice medicine, and work at the Andrews Institute is focusing on leading the way but also producing proof that these methods are making a difference in the lives of our patients.

If you have questions about platelet rich plasma, bone marrow aspirate, or stem cells please contact the Gulf Breeze, Florida orthopedic surgeon, Dr. Adam Anz located at the Andrews Institute.

Interview

AAOS Now Interview

by Meniscus
Interview

Dr. Anz was interviewed regarding his JAAOS article examining the application of biologics for the rotator cuff, meniscus, and cartilage by AAOS Now, the official member newsmagazine of the American Academy of Orthopaedic Surgeons.

Maureen Leahy asks:
Biologics have been used for some time in medicine. What is their role in orthopedics?

Dr. Anz:
In my opinion, biologics represent the next frontier in orthopedics.  During the past 30 years, particularly in sports medicine, the focus has been on the use of the arthroscope, which revolutionized how we performed treatments.  I believe biologics will revolutionize the next 30 years. 

Maureen Leahy: 
Are each of these biologic technologies equally important?

Dr. Anz:
I don’t think any one of them is more important or warrants more study than the others.  PRP, BMA, and stem cells are like arrows in a quiver.  In some instances, PRP will be the right arrow to use; in a different situation, BMA might be more appropriate.  From a regulatory standpoint, PRP and BMA are the arrows we can use right now.  The FDA has made it clear that it is going to take a tough stance on stem cells, no matter what the harvest site-and rightfully so. It will be exciting, however, once we can use them. 

For more about AAOS, visit:

http://www.aaos.org/

AAOS-interview